In addition, I am involved as co-PI in a number of international collaborations, e.g.
My total research grant income as PI amounts to more than 3.2 million euros, of which >440,000 euros were secured in the last three years. Chapters from Drug Absorption Studies, a book edited by me and published by Springer in 2008, were downloaded >85,000 times, placing it in the top 25% most downloaded eBooks in the relevant eBook Collection in 2016. it has received enough citations to place it in the top 1% of its academic field based on a highly cited threshold for the field and publication year. 2011) achieved highly cited paper status according to Essential Science Indicators, i.e. Another of our publications (Paszko et al. One of the highlights of our endeavours so far was the invitation to publish a review article in Nature Chemistry (Zelikin et al.
My lab continuously publishes in in high ranking peer-reviewed journals in the subject areas of Pharmaceutics, Pharmacology and Physiology. James's Hospital, Brigham Young University, University of Kanazawa and University Medical Center Groningen and is financially supported by a Clinical Investigator Award from the Flight Attendant Medical Research Institute (FAMRI). This study brings together researcher from TCD, St. the role of ergothioneine and its physiological transporter OCTN1 in the development and progression of tobacco-related chronic obstructive pulmonary disease (COPD). At the moment, we are involved in a number of international, multidisciplinary, translational studies into the role that drug transporters play in the pathogenesis of lung diseases. The unique combination of cell physiological basis and pharmaceutical application has led to numerous research collaborations, nationally and internationally, as well as to a continuous stream of visiting researchers to my laboratory. The expertise of my laboratory includes techniques from the areas of pharmaceutics, pharmacokinetics, pharmacology, electrophysiology, cell and molecular biology and immunocytochemistry. Inter alia, we have been credited with pioneering the development of primary cultures of human alveolar epithelial cells. We have established organotypic in vitro, ex vivo and experimental in vivo models, which allow a wide array of discovery and development studies. In my lab we primarily employ pre-clinical models. With 1 in 7 people in Ireland having an undiagnosed lung condition and Ireland having the third highest death rate from lung disease in Europe, causing 1 in 5 deaths, the potential impact of my work becomes clear. Over the last 20 years, the incidence of lung-related diseases and the morbidity due to these conditions is increasing at more than 5% per year. Moreover, I have developed a keen interest in the molecular origins of lung disease. lung drug disposition and pulmonary epithelial transport. The scientific aim of my work is to describe the behaviour of drugs following their administration to the lung as inhaled aerosols, i.e. I have established an international reputation in the field of Pulmonary Biopharmaceutics. He is Section Editor of European Journal of Pharmceutical Sciences and he actively serves on the Editorial Boards of the American Journal of Physiology - Lung Cellular and Molecular Physiology, Journal of Aerosol Medicine and Pulmonary Drug Delivery, Journal of Pharmaceutical Sciences and European Journal of Pharmaceutics and Biopharmaceutics. Carsten is the proud recipient of honours and awards from DPhG, APS and Galenus Foundation. He is a member of Gesellschaft für Wehrmedizin und Wehrpharmazie (VdSO), Deutsche Pharmazeutische Gesellschaft (DPhG), American Association of Pharmaceutical Scientists (AAPS), International Society for Aerosols in Medicine (ISAM), American Physiological Society (APS) and Japanese Society for the Study of Xenobiotics (JSSX). Carsten has given over 120 invited oral presentations at research institutions, international conferences and workshops.
He has edited 1 book and (co-)authored 91 peer-reviewed publications, 12 book chapters and more than 240 abstracts and conference proceedings. His research is focused on lung drug disposition, pulmonary epithelial transport and molecular origins of airways disease. degree in Biopharmaceutics from Saarland University in 2003. He was elected Fellow of Trinity College Dublin in 2013. In addition, he is holding the position of Adjunct Associate Professor in the School of Pharmacy, University of Southern California. Carsten Ehrhardt is Professor in Pharmaceutics and Biopharmaceutics at the School of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin.
0 kommentar(er)
